A rapid immunoassay for the simultaneous direct detection and differential diagnosis of SARS-CoV-2, influenza type A and type B antigens from anterior nasal and nasopharyngeal swab specimens.
- COVID-19
- Anterior nasal swab specimen ? Sensitivity 93.8 %, Specificity 100%
- Nasopharyngeal ? Sensitivity 93.1 %, Specificity 100%
- Flu A - Sensitivity 91.4%, Specificity 95.7%
- Flu B - Sensitivity 87.6%, Specificity 95.9%
- FDA Emergency Use Authorization (EUA)
- Visually read in 15 minutes
- Flocked nasopharyngeal swab for superior specimen collection and patient comfort